23andMe Investor Day Presentation Deck

Preclinical Data Supports Combining CD96 with PD-1 and TIGIT Inhibitors CD96, TIGIT and PD-1 Combination Suggests Synergy Mean tumor size (mm²) 200 150- 100- 50- 0 clg aCD96- BaPD1 A&TIGIT (G2a) e aCD96+ aTIGIT (G2a) aPD1+aCD96 aPD1+ aTIGIT (G2a) aPD1 + TIGIT (G2a) + aCD96 .**.**. 0 5 10 15 20 25 30 35 40 45 50 55 Days after CT26 tumor inoculation Cancer Immunol Res. 2019;7(4):559 Anti-CD96 + Anti-TIGIT + Anti-PD1 Combination CD226 pathway components owned by GSK Component Molecule PD-1 CD96 PVRIG TIGIT Dostarlimab GSK'608 SRF813 GSK4428859 (EOS448) Partner Acquired from Tesaro 23andMe In-license from Surface Oncology iTeos Copyright © 2022 23andMe, Inc. 23andMe® 46

View entire presentation